Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

A new systematic review identifies 17 modifiable risk factors shared by stroke, dementia, and late-life depression — offering ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

My 15-year-old cat looms over me where I lie in bed, pretending I don’t see her. “Meow,” she says plaintively. I gently shrug ...

Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and ...

and pulmonary hypertension may be particularly relevant to the pathophysiology heart failure in patients with preserved ejection fraction, there is compelling rationale for extending the ...

Chronic cluster headache is undoubtedly one of the toughest clinical challenges of headache medicine. The amount of pain and distress experienced by people with this condition sometimes justifies ...